Farmakoterapiya diabeticheskoy nevropatii: chto eshche krome kontrolya glikemii?


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents the current knowledge about the nature of diabetic neuropathy (DN) and its most common form - the distal neuropathy. Severe manifestations of DN occur in approximately 10 % of patients with diabetes mellitus. Widely use of complex preparations of B vitamins - Milgamma and Milgamma compositum (contains fat-soluble derivative of thiamine - benfotiamine) in the treatment of distal DN is substantiated. Application of Milgamma and Milgamma compositum greatly increases the potentials of pharmacotherapy of distal DN, allows to improve the quality of life and prognosis of patients.

Full Text

Restricted Access

About the authors

E. V Biryukova

Email: lena@obsudim.ru

T. B Danilova

References

  1. Said G. Diabetic Neuropathy. A Review. Nat Clin Pract Neurol 2007;3(6):331 -40.
  2. Kempler P (ed). Neuropathies. Pathomechanism, clinical presentation, diagnosis, therapy. Budapest: Springer Scientific Publisher, 2002.
  3. Boulton AJM, Kirsner RS, Vileikyte L. Neuropathic diabetic foot ulcers. N Engl J Med 2004; 351:48-55.
  4. Happich M, John J, Stamenitis S, Clouth J, Polnau D. The quality of life and economic burden of neuropathy in diabetic patients in Germany in 2002 - results from the Diabetic Microvascular Complications (DIMICO) study. DiabetesRes Clin Pract 2008;81:223-30.
  5. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes 2005;54:1615-25.
  6. Boulton AJM, Vileikyte L, Ragnarson-Tennwall G, Apelqvist J. The global burden of diabetic foot disease. Lancet 2005;366:1719-24.
  7. Fazan VPS, de Vasconcelos CAC, Valenc MM. Diabetic peripheral neuropathies: a morphometric overview. Int J Morphol 2010;28( 1 ):51-64.
  8. Vinik AI, Maser RE, Mitchell BD, et al. Diabetic Autonomic Neuropathy. Diabetes Care 2003;26:1553-79.
  9. Ziegler D. Diabetic cardiovascular autonomic neuropathy: prognosis, diagnosis, and treatment. Diabetes Metab Rev 1994; 10:339-83.
  10. Spallone V, Ziegler D, Freeman R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev 2011; 27:639-53.
  11. DCCT: The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
  12. Строков И.А., Строков К.И., Альбекова Ж.С. Бенфотиамин в клинической практике // Лечащий врач 2009. № 11. С. 56-61.
  13. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
  14. Russell JW, Feldman EL. Impaired glucose tolerance - does it cause neuropathy? Muscle Nerve 2001;24:1109-12.
  15. Herman WH, Kennedy L. Underdiagnosis of peripheral neuropathy in type 2 diabetes. Diabetes Care 2005;28:1480-81.
  16. Marshall S, Flyvbjerg A. Prevention and early detection of vascular complications of diabetes. BMJ 2006;333:475-80.
  17. Jermendy G, for Benfotiamine Trial. Use of benfotiamine for treating diabetic polyneuropathy (Hungarian multicenter trial). Hung Arch Int Med 1996;4:223-26.
  18. Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003; 9:294-99.
  19. Thornalley PJ. The potential role of thiamine (vitamin B1) in diabetic complications. Curr Diabetes Rev 2005;1:287-98.
  20. Balakumar P, Rohilla A, Krisha P, et al. The multifaceted therapeutic potential of benfotiamine. Pharmacol Res 2010;61 ;482-88.
  21. Thornalley PJ, Babaei-Jadidi R, Al Ali H, et al. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia 2007;50:2 164-70.
  22. Berrone E, Beltramo E, Solimine C, et al. Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J Biol Chem 2006; 14:9307-13.
  23. Haupt E, Ledermann H, Kopcke W. Benfotiamine in the treatment of diabetic polyneuropathy -a three-week randomized controlled pilot-study (BEDIP study). Int J Clin Pharmacol Ther 2005;43:71-7.
  24. Stracke H, Gaus W, Achenbach U, et al. Benfotiamine in Diabetic Polyneuropathy (BENDIP): Results of a randomised, double-blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes 2008;116:600-05.
  25. Анциферов М.Б. Волковой А.К. Диагностика и лечение диабетической дистальной полинейропатии у больных сахарным диабетом в амбулаторной практике // РМЖ. Эндокринология 2008. Т. 16. № 15. С. 1-7.
  26. Rabbani N, Shahzad Alam S, Riaz, et al. High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a pilot randomized, double-blind placebo-controlled study. Diabetologia 2009;52:208-12.
  27. Mooney S, Leuendorf J-E, Hendrickson C, Hellmann H. Vitamin Be: A Long Known Compound of Surprising Complexity. Molecules 2009; 14:329-51.
  28. Stracke H, Lindemann A, Federlin K. A benfotiamine - vitamin B combination in the treatment of diabetic polyneuropathy. Exp Clin Endocrin Diabetes 1996;104:311-16.
  29. Solomon LR. Disorders of cobalamin (vitamin B12) metabolism: emerging concept in patophysiology, diagnosis and treatment. Blood Rev 2007;21:113-30.
  30. Simeonov S, Pavlova M, Mitkov M, et al. Therapeutic efficacy of Milgamma in patients with painful diabetic neuropathy. Folia Med (Plovdiv) 1997;39(4):5-10.
  31. Воробьев С.В., Кириченко Д.А., Синанян Т.Б. Влияние бенфотиамина на клинические и инструментальные проявления автономной нейропатии при сахарном диабете 2 типа в комплексной патогенетической терапии нейропатии // Биомедицина 2006. № 3. С. 100-01.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies